B20 F32
Conditions
Interventions
Group 1: Intervention arm: Participants in this arm will receive routine depression diagnosis using PHQ-9 and management using interpersonal psychotherapy combined with pharmacotherapy where appropria
Sponsors
Research for Development international Foundation
Eligibility
Sex/Gender
All
Age
13 Years to 80 Years
Inclusion criteria
Inclusion criteria: Any person 13 years and above who is living with HIV who has been on treatment 6-9months prior start of the study. This person has to be aware of their serological status and implicated in their treatment.
Exclusion criteria
Exclusion criteria: Persons 10-12 years of age, prisoners, those who were unable to understand the study as well as those who were not aware of their serological status nor implicated in their treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The antiretroviral treatment suppression levels of the participants will be measured at the endpoint of the study using viral load measurement system setup within the country (GeneXpert® HIV-1 Viral Load, Cepheid or Generic HIV-1 Charge Virale, Biocentric). Any participant will be considered suppressed if the viral load was less than 1000 copies per ml. | — |
Secondary
| Measure | Time frame |
|---|---|
| The antiretroviral treatment adherence levels of participants will be measured at baseline, at month-6, and at month-12 of follow-up using the multi-method adherence measurement tool which is a questionnaire constituting of drug refill, pill identification test, self-reported adherence, visual analog scale, and pill count. This tool is overall graded from 5-10 where participants will be considered poorly, moderately, and highly adherent if they have scores between 5-9, 10-14, and 15 respectively. | — |
Countries
Cameroon
Contacts
Public ContactJackson Jr Ndenkeh
Research for Development international Foundation
Outcome results
None listed